Wordt geladen...
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma
T cell checkpoint blockade with antibodies targeting programmed cell death (ligand)-1 (PD-1/PD-L1) and/or cytotoxic T lymphocyte-antigen 4 (CTLA-4) has improved therapy outcome in melanoma patients. However, a considerable proportion of patients does not benefit even from combined α-CTLA-4 and α-PD-...
Bewaard in:
| Gepubliceerd in: | Cancer Immunol Immunother |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer Berlin Heidelberg
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4880641/ https://ncbi.nlm.nih.gov/pubmed/27160390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1843-4 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|